| Market Cap | 1.75B | P/E | 73.83 | EPS this Y | 178.10% | Ern Qtrly Grth | 1,288.70% |
| Income | 23.14M | Forward P/E | 33.94 | EPS next Y | 22.50% | 50D Avg Chg | - |
| Sales | 437.66M | PEG | 2.76 | EPS past 5Y | -18.79% | 200D Avg Chg | 11.00% |
| Dividend | 1.00% | Price/Book | 3.51 | EPS next 5Y | 15.00% | 52W High Chg | -11.00% |
| Recommedations | 3.00 | Quick Ratio | 5.92 | Shares Outstanding | 47.31M | 52W Low Chg | 79.00% |
| Insider Own | 4.35% | ROA | 5.06% | Shares Float | 41.76M | Beta | 0.57 |
| Inst Own | 92.55% | ROE | 4.97% | Shares Shorted/Prior | 2.02M/2.35M | Price | 36.99 |
| Gross Margin | 60.31% | Profit Margin | 5.39% | Avg. Volume | 663,341 | Target Price | 37.00 |
| Oper. Margin | 12.49% | Earnings Date | Nov 3 | Volume | 1,017,936 | Change | 0.00% |
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
| Piper Sandler | Neutral | Apr 13, 21 |
| BTIG | Neutral | Apr 13, 21 |
| JP Morgan | Underweight | Sep 27, 19 |
| Citigroup | Neutral | Nov 6, 18 |
| Citigroup | Neutral | Jul 23, 18 |
| Deutsche Bank | Hold | May 7, 18 |
| BTIG Research | Buy | Jan 5, 18 |
| Deutsche Bank | Sell | Jan 18, 17 |
| Deutsche Bank | Sell | Jan 17, 17 |